Baxter Healthcare Corporation Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Baxter Healthcare Corporation Pharmaceutical Import Records from India — 5 Products, $11.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Baxter Healthcare Corporation — Pharmaceutical Importer Profile (2026) | 5 Products, $11.8M Trade | TransData Nexus

Baxter Healthcare Corporation

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $11.8M Total Trade · DGFT Verified

Baxter Healthcare Corporation is a pharmaceutical importer based in United States with a total trade value of $11.8M across 5 products in 5 therapeutic categories. Based on 237 verified import shipments from Indian Customs (DGFT) records, Baxter Healthcare Corporation is the #1 buyer in 1 product including Furosemide. Baxter Healthcare Corporation sources from 4 verified Indian suppliers, with Caplin Steriles Limited accounting for 57.9% of imports.

Baxter Healthcare Corporation — Import Portfolio & Supplier Network

Baxter Healthcare Corporation import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Baxter Healthcare Corporation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Caplin Steriles Limited	$15.3M	465	57.9%
Baxter Pharmaceuticals India Private Limited	$7.2M	168	27.2%
Gland Pharma Limited

What Formulations Does Baxter Healthcare Corporation Import?

Formulation	Value	Ships
Norepinephrine bitartrate injection	$1.1M	21
Ropivacaine hydrochloride injection	$729.8K	22
Pharmaceutical formulations-ketorolac	$680.6K	15
Furosemide INJ USP 10MG/ml4mlgv	$600.0K	12
Pharmaceutical formulations	$591.7K	12
Ropivacaine hydrochloride injection USP,0.2%, 200MG/100ML (2MG/ML) 100ML	$522.2K	13
Pharmaceutical formulations	$459.3K	14
Furosemide injection usp10mg/ML 10ML	$450.0K	9
Ondansetron INJ USP 2 MG/ML 2ML	$367.9K	12
Metoprolol tartrate injectionusp 1MG/ml5ml glass vial	$357.1K	9
Norepinephrine bitartrate injection usp4mg/4ML (1MG/ML	$354.5K	9
Furosemide INJ USP 10MG/ml2mlgv	$350.0K	7
Pharmaceutical formulationslabetalol	$313.4K	11
Pharmaceutical formulations-ropivacaine	$301.7K	10
Furosemide injection usp10mg/ML 10ML	$300.0K	6

Baxter Healthcare Corporation imports 277 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ketorolac	Analgesics & Antipyretics	$6.0M	119	5.1%	4
2	Furosemide	Diuretics	$3.4M	68	4.4%	1
3	Ondansetron	Gastrointestinal	$1.3M	26	1.1%	17
4	Tobramycin	Antibiotics	$600.0K	12	1.5%	14
5	Verapamil	Cardiovascular	$600.0K	12	0.5%	10

Baxter Healthcare Corporation imports 5 pharmaceutical products across 5 categories into United States totaling $11.8M. The company is the #1 buyer for 1 product: Furosemide.

Baxter Healthcare Corporation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Baxter Healthcare Corporation, a subsidiary of Baxter International Inc., is a global leader in medical products and healthcare solutions, dedicated to saving and sustaining lives through innovation and advanced patient care. With over 90 years of experience, Baxter's products and therapies are utilized across various healthcare settings, including hospitals, clinics, and home care environments.

Headquartered in Deerfield, Illinois, USA, Baxter operates in more than 100 countries, offering a diverse portfolio that encompasses diagnostic, critical care, nutrition, hospital, and surgical products. The company's mission is to provide essential building blocks of healthcare, touching the lives of millions of patients, caregivers, and healthcare providers daily.

2Distribution Network

Baxter Healthcare Corporation maintains a comprehensive distribution network to ensure the timely delivery of its products across the United States and internationally. While specific warehouse locations are not publicly disclosed, the company operates multiple distribution centers strategically positioned to serve various regions efficiently. This extensive network supports the company's commitment to providing critical medical products and services to healthcare providers and patients worldwide.

3Industry Role

In the United States pharmaceutical supply chain, Baxter Healthcare Corporation functions as a primary wholesaler and distributor. The company sources a wide range of pharmaceutical products, including finished formulations, from various suppliers, including those in India. Baxter's role is pivotal in ensuring the availability of essential medications and medical products to healthcare providers and patients across the nation.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Baxter Healthcare Corporation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Baxter Healthcare Corporation's sourcing strategy reveals a significant concentration in its supplier base, particularly from India. The company has imported finished pharmaceutical formulations totaling $11.8 million USD from India, encompassing 237 shipments across five therapeutic categories. The top five products imported include Furosemide ($3.4 million, 4.4% share), Ketorolac ($6.0 million, 5.1% share), Ondansetron ($1.3 million, 1.1% share), Tobramycin ($600,000, 1.5% share), and Verapamil ($600,000, 0.5% share). Notably, Baxter is the leading buyer of Furosemide, indicating a strategic focus on this product.

The supplier concentration is as follows:

CAPLIN STERILES LIMITED: $15.3 million (57.9% of shipments)
BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED: $7.2 million (27.2% of shipments)
GLAND PHARMA LIMITED: $3.9 million (14.9% of shipments)
EXTROVIS PRIVATE LIMITED: $0 (0.0% of shipments)

This concentration suggests a strategic choice to maintain strong relationships with key suppliers, ensuring consistent product quality and supply. However, it also presents a potential risk if any of these suppliers face operational challenges or regulatory issues.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the primary regulatory authority overseeing pharmaceutical imports is the U.S. Food and Drug Administration (FDA). The FDA enforces regulations to ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for drug approval, manufacturing, and distribution.

For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process. This pathway allows for the approval of generic drugs based on their bioequivalence to the brand-name counterpart, facilitating market entry while ensuring therapeutic equivalence.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Manufacturers must obtain FDA approval for each drug product, demonstrating compliance with Current Good Manufacturing Practice (CGMP) regulations. Recognized certifications include EU GMP, WHO GMP, and PIC/S, which are accepted by the FDA as evidence of manufacturing quality.

Wholesale distribution authorization is also required, ensuring that distributors meet specific standards for storage, handling, and distribution of pharmaceutical products. This authorization is crucial for maintaining the integrity and safety of the drug supply chain.

Baxter Healthcare Corporation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Baxter Healthcare Corporation's focus on importing specific therapeutic categories—Analgesics & Antipyretics (50.2%), Diuretics (28.7%), and Gastrointestinal (11.0%)—aligns with market demand for essential medications in these areas. The top five imported products, including Furosemide and Ketorolac, are critical in managing conditions such as pain, hypertension, and gastrointestinal disorders.

This strategic focus ensures that Baxter meets the needs of healthcare providers and patients by supplying vital medications that address prevalent health conditions.

2Sourcing Profile

Baxter Healthcare Corporation's sourcing strategy emphasizes the procurement of generic drugs, particularly from India, due to the country's robust pharmaceutical manufacturing capabilities and cost-effectiveness. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-use products that meet stringent quality standards.

India's established reputation for producing high-quality generics makes it a preferred sourcing destination for Baxter, enabling the company to offer a diverse and reliable product portfolio to the U.S. market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Baxter Healthcare Corporation

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Baxter Healthcare Corporation's supply chain, provided they can meet the company's stringent quality standards and regulatory requirements. Gaps in Baxter's current sourcing include potential diversification of suppliers to mitigate risks associated with supplier concentration.

Indian exporters can capitalize on this opportunity by

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Baxter Healthcare Corporation

What products does Baxter Healthcare Corporation import from India?

Baxter Healthcare Corporation imports 5 pharmaceutical products across 5 categories. Top imports: Ketorolac ($6.0M), Furosemide ($3.4M), Ondansetron ($1.3M), Tobramycin ($600.0K), Verapamil ($600.0K).

Who supplies pharmaceuticals to Baxter Healthcare Corporation from India?

Baxter Healthcare Corporation sources from 4 verified Indian suppliers. The primary supplier is Caplin Steriles Limited (57.9% of imports, $15.3M).

What is Baxter Healthcare Corporation's total pharmaceutical import value?

Baxter Healthcare Corporation's total pharmaceutical import value from India is $11.8M, based on 237 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Baxter Healthcare Corporation focus on?

Baxter Healthcare Corporation imports across 5 categories. The largest: Analgesics & Antipyretics (50.2%), Diuretics (28.7%), Gastrointestinal (11.0%).

Get Full Baxter Healthcare Corporation Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.